Nichole Carlson
Concepts (546)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoidosis, Pulmonary | 3 | 2025 | 84 | 1.470 |
Why?
| | Bayes Theorem | 6 | 2020 | 412 | 1.210 |
Why?
| | Luteinizing Hormone | 11 | 2020 | 183 | 1.050 |
Why?
| | Outpatients | 8 | 2025 | 419 | 1.000 |
Why?
| | Tomography, X-Ray Computed | 5 | 2025 | 2698 | 0.980 |
Why?
| | Models, Statistical | 6 | 2020 | 663 | 0.950 |
Why?
| | Sarcoidosis | 2 | 2025 | 158 | 0.930 |
Why?
| | Hydrocortisone | 6 | 2015 | 314 | 0.870 |
Why?
| | Hormones | 3 | 2017 | 140 | 0.800 |
Why?
| | Emphysema | 1 | 2023 | 116 | 0.760 |
Why?
| | Hypothalamo-Hypophyseal System | 7 | 2017 | 205 | 0.700 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 748 | 0.660 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 311 | 0.650 |
Why?
| | Diabetes Complications | 1 | 2022 | 223 | 0.650 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 364 | 0.640 |
Why?
| | Radiography, Thoracic | 2 | 2024 | 172 | 0.630 |
Why?
| | Disease Susceptibility | 1 | 2021 | 349 | 0.590 |
Why?
| | Metadata | 1 | 2018 | 14 | 0.580 |
Why?
| | State Health Plans | 2 | 2008 | 34 | 0.550 |
Why?
| | Computer Simulation | 4 | 2017 | 996 | 0.550 |
Why?
| | Follicle Stimulating Hormone | 9 | 2023 | 243 | 0.530 |
Why?
| | Models, Biological | 3 | 2017 | 1806 | 0.530 |
Why?
| | Ovary | 3 | 2017 | 223 | 0.520 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2015 | 148 | 0.500 |
Why?
| | Genome | 1 | 2018 | 299 | 0.490 |
Why?
| | Reproduction | 1 | 2017 | 202 | 0.490 |
Why?
| | Alzheimer Disease | 5 | 2025 | 564 | 0.480 |
Why?
| | Child Health Services | 2 | 2008 | 191 | 0.470 |
Why?
| | Residence Characteristics | 6 | 2010 | 363 | 0.470 |
Why?
| | Humans | 97 | 2025 | 138651 | 0.460 |
Why?
| | Contraceptives, Oral, Combined | 7 | 2011 | 18 | 0.450 |
Why?
| | Biometry | 2 | 2017 | 69 | 0.430 |
Why?
| | Health Services for the Aged | 2 | 2019 | 72 | 0.430 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2021 | 622 | 0.430 |
Why?
| | Software | 2 | 2019 | 668 | 0.430 |
Why?
| | Obesity | 12 | 2023 | 2962 | 0.430 |
Why?
| | Female | 74 | 2025 | 73763 | 0.430 |
Why?
| | Brain Injuries | 5 | 2010 | 501 | 0.420 |
Why?
| | Computational Biology | 1 | 2018 | 649 | 0.420 |
Why?
| | Adult | 53 | 2025 | 38201 | 0.400 |
Why?
| | Pulsatile Flow | 1 | 2013 | 55 | 0.400 |
Why?
| | Antiparkinson Agents | 3 | 2009 | 40 | 0.400 |
Why?
| | Environment Design | 3 | 2010 | 26 | 0.400 |
Why?
| | Antibodies, Monoclonal | 6 | 2025 | 1436 | 0.390 |
Why?
| | Antibodies, Viral | 5 | 2024 | 649 | 0.390 |
Why?
| | Dehydroepiandrosterone | 1 | 2013 | 51 | 0.390 |
Why?
| | Circadian Rhythm | 4 | 2013 | 489 | 0.390 |
Why?
| | Aged | 29 | 2025 | 24024 | 0.390 |
Why?
| | Health Services Accessibility | 4 | 2010 | 989 | 0.380 |
Why?
| | Middle Aged | 39 | 2025 | 33604 | 0.370 |
Why?
| | Specimen Handling | 1 | 2013 | 180 | 0.350 |
Why?
| | Gonadotropins | 3 | 2023 | 40 | 0.350 |
Why?
| | Saliva | 1 | 2013 | 238 | 0.350 |
Why?
| | Male | 46 | 2025 | 68260 | 0.340 |
Why?
| | Walking | 4 | 2010 | 535 | 0.330 |
Why?
| | White Matter | 2 | 2023 | 144 | 0.320 |
Why?
| | Oregon | 8 | 2011 | 73 | 0.320 |
Why?
| | Levodopa | 2 | 2007 | 39 | 0.320 |
Why?
| | Lung | 5 | 2025 | 4106 | 0.320 |
Why?
| | Hypogonadism | 2 | 2015 | 92 | 0.320 |
Why?
| | Antibodies, Neutralizing | 4 | 2025 | 302 | 0.310 |
Why?
| | Hospitalization | 8 | 2024 | 2235 | 0.310 |
Why?
| | Endocrine System | 1 | 2009 | 21 | 0.310 |
Why?
| | Activities of Daily Living | 3 | 2010 | 421 | 0.300 |
Why?
| | Statistics as Topic | 3 | 2025 | 298 | 0.300 |
Why?
| | Parkinson Disease | 4 | 2009 | 556 | 0.300 |
Why?
| | Testosterone | 2 | 2010 | 402 | 0.290 |
Why?
| | Prenatal Care | 1 | 2010 | 295 | 0.280 |
Why?
| | Technology | 1 | 2009 | 94 | 0.280 |
Why?
| | Estradiol | 6 | 2023 | 525 | 0.280 |
Why?
| | Cerebral Ventricles | 1 | 2007 | 54 | 0.270 |
Why?
| | Levonorgestrel | 4 | 2011 | 36 | 0.270 |
Why?
| | Cognition Disorders | 3 | 2008 | 511 | 0.270 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2490 | 0.270 |
Why?
| | Metrorrhagia | 3 | 2011 | 4 | 0.270 |
Why?
| | Health Behavior | 3 | 2010 | 773 | 0.270 |
Why?
| | Aged, 80 and over | 12 | 2025 | 7677 | 0.260 |
Why?
| | Perception | 2 | 2007 | 369 | 0.260 |
Why?
| | Methylphenidate | 1 | 2007 | 42 | 0.260 |
Why?
| | Young Adult | 15 | 2024 | 13305 | 0.260 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 60 | 0.260 |
Why?
| | Smoking Cessation | 1 | 2010 | 436 | 0.250 |
Why?
| | Time Factors | 13 | 2017 | 6851 | 0.230 |
Why?
| | Longitudinal Studies | 10 | 2020 | 2844 | 0.230 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3706 | 0.230 |
Why?
| | Poverty | 2 | 2010 | 523 | 0.230 |
Why?
| | Cluster Analysis | 2 | 2023 | 517 | 0.220 |
Why?
| | Gliosis | 2 | 2023 | 28 | 0.220 |
Why?
| | Health Care Rationing | 1 | 2024 | 59 | 0.210 |
Why?
| | Adenosine Monophosphate | 1 | 2024 | 67 | 0.210 |
Why?
| | Brain Ischemia | 2 | 2017 | 343 | 0.210 |
Why?
| | Healthcare Disparities | 1 | 2010 | 659 | 0.210 |
Why?
| | Denmark | 2 | 2021 | 47 | 0.210 |
Why?
| | Alanine | 1 | 2024 | 152 | 0.210 |
Why?
| | Medicaid | 1 | 2008 | 447 | 0.210 |
Why?
| | Neurology | 1 | 2025 | 111 | 0.210 |
Why?
| | Spirometry | 2 | 2024 | 263 | 0.200 |
Why?
| | Risk Factors | 10 | 2022 | 10252 | 0.200 |
Why?
| | Retrospective Studies | 13 | 2024 | 15909 | 0.190 |
Why?
| | Oocytes | 2 | 2020 | 179 | 0.190 |
Why?
| | Body Mass Index | 6 | 2019 | 2349 | 0.190 |
Why?
| | Neuropsychological Tests | 3 | 2025 | 1058 | 0.190 |
Why?
| | Socioeconomic Factors | 5 | 2010 | 1296 | 0.190 |
Why?
| | Benchmarking | 1 | 2023 | 187 | 0.180 |
Why?
| | Aging | 4 | 2008 | 1855 | 0.180 |
Why?
| | Monte Carlo Method | 3 | 2017 | 143 | 0.180 |
Why?
| | Markov Chains | 3 | 2017 | 126 | 0.180 |
Why?
| | Respiratory Function Tests | 2 | 2024 | 561 | 0.180 |
Why?
| | Prospective Studies | 9 | 2023 | 7554 | 0.180 |
Why?
| | Cross-Sectional Studies | 12 | 2018 | 5520 | 0.180 |
Why?
| | Antiviral Agents | 2 | 2024 | 735 | 0.180 |
Why?
| | Cohort Studies | 7 | 2025 | 5697 | 0.180 |
Why?
| | Disability Evaluation | 4 | 2018 | 299 | 0.170 |
Why?
| | Doxycycline | 2 | 2011 | 61 | 0.170 |
Why?
| | Ethinyl Estradiol | 2 | 2011 | 15 | 0.170 |
Why?
| | Oocyte Donation | 1 | 2020 | 4 | 0.170 |
Why?
| | Preimplantation Diagnosis | 1 | 2020 | 5 | 0.170 |
Why?
| | Weight Gain | 2 | 2022 | 532 | 0.170 |
Why?
| | Healthy Aging | 1 | 2021 | 36 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 98 | 0.170 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 102 | 0.170 |
Why?
| | Prescription Drugs | 1 | 2022 | 112 | 0.170 |
Why?
| | Memory, Episodic | 1 | 2021 | 52 | 0.170 |
Why?
| | Myocardial Infarction | 2 | 2017 | 1059 | 0.160 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2020 | 39 | 0.160 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 195 | 0.160 |
Why?
| | Cross-Over Studies | 6 | 2025 | 556 | 0.160 |
Why?
| | Apomorphine | 3 | 2009 | 7 | 0.160 |
Why?
| | Proton Pump Inhibitors | 2 | 2017 | 108 | 0.160 |
Why?
| | Menstruation | 2 | 1991 | 42 | 0.160 |
Why?
| | Fractals | 1 | 2019 | 8 | 0.160 |
Why?
| | Aromatase Inhibitors | 1 | 2020 | 58 | 0.160 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 23 | 0.160 |
Why?
| | Nerve Compression Syndromes | 1 | 1999 | 22 | 0.160 |
Why?
| | Radial Nerve | 1 | 1999 | 10 | 0.160 |
Why?
| | Severity of Illness Index | 7 | 2024 | 2851 | 0.160 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3307 | 0.150 |
Why?
| | Internet | 2 | 2018 | 669 | 0.150 |
Why?
| | Human Growth Hormone | 2 | 2014 | 48 | 0.150 |
Why?
| | Machine Learning | 1 | 2024 | 517 | 0.150 |
Why?
| | Astrocytes | 1 | 2021 | 216 | 0.150 |
Why?
| | Health Status | 3 | 2010 | 819 | 0.150 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1229 | 0.150 |
Why?
| | Quality of Life | 5 | 2018 | 2954 | 0.150 |
Why?
| | Hip Fractures | 1 | 2019 | 86 | 0.150 |
Why?
| | Biomedical Research | 1 | 2025 | 694 | 0.140 |
Why?
| | Vital Capacity | 1 | 2019 | 312 | 0.140 |
Why?
| | Datasets as Topic | 1 | 2018 | 125 | 0.140 |
Why?
| | Bibliometrics | 1 | 2018 | 65 | 0.140 |
Why?
| | Sheep, Domestic | 1 | 2017 | 34 | 0.140 |
Why?
| | Regression Analysis | 2 | 2019 | 1017 | 0.140 |
Why?
| | Case-Control Studies | 5 | 2021 | 3523 | 0.140 |
Why?
| | Contraception | 2 | 1991 | 160 | 0.140 |
Why?
| | Anxiety | 1 | 2025 | 1072 | 0.140 |
Why?
| | Eligibility Determination | 2 | 2008 | 68 | 0.130 |
Why?
| | Reproductive Physiological Phenomena | 1 | 2017 | 1 | 0.130 |
Why?
| | Adolescent | 14 | 2024 | 21564 | 0.130 |
Why?
| | Algorithms | 3 | 2017 | 1740 | 0.130 |
Why?
| | Medically Uninsured | 2 | 2008 | 135 | 0.130 |
Why?
| | Rhinitis | 2 | 2010 | 171 | 0.130 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 741 | 0.130 |
Why?
| | Premature Birth | 1 | 2020 | 335 | 0.130 |
Why?
| | Metabolic Diseases | 1 | 2018 | 109 | 0.130 |
Why?
| | Lactation | 1 | 2018 | 174 | 0.130 |
Why?
| | Family Planning Services | 2 | 2008 | 91 | 0.130 |
Why?
| | Psychomotor Performance | 3 | 2009 | 317 | 0.130 |
Why?
| | Hypothyroidism | 2 | 2007 | 73 | 0.130 |
Why?
| | Affect | 3 | 2008 | 312 | 0.130 |
Why?
| | Double-Blind Method | 7 | 2011 | 1949 | 0.130 |
Why?
| | Pregnancy | 8 | 2023 | 6829 | 0.120 |
Why?
| | Antibodies | 1 | 2018 | 404 | 0.120 |
Why?
| | Endoscopy | 2 | 2010 | 320 | 0.120 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2018 | 177 | 0.120 |
Why?
| | Low Back Pain | 1 | 2018 | 107 | 0.120 |
Why?
| | Dietary Fats | 1 | 2018 | 299 | 0.120 |
Why?
| | Sinusitis | 2 | 2010 | 237 | 0.120 |
Why?
| | Immunologic Memory | 1 | 2018 | 357 | 0.120 |
Why?
| | Models, Animal | 1 | 2017 | 395 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2021 | 370 | 0.120 |
Why?
| | Brain | 6 | 2023 | 2792 | 0.120 |
Why?
| | Personnel Selection | 1 | 2016 | 79 | 0.120 |
Why?
| | Recovery of Function | 2 | 2010 | 665 | 0.120 |
Why?
| | Otolaryngology | 1 | 2016 | 98 | 0.110 |
Why?
| | Patient Dropouts | 1 | 2015 | 62 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2015 | 119 | 0.110 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 1 | 2014 | 12 | 0.110 |
Why?
| | Acromegaly | 1 | 2014 | 16 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 235 | 0.110 |
Why?
| | Pituitary-Adrenal System | 3 | 2013 | 170 | 0.110 |
Why?
| | Menstrual Cycle | 3 | 2011 | 133 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 139 | 0.110 |
Why?
| | Breast Feeding | 1 | 2018 | 422 | 0.110 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2020 | 212 | 0.110 |
Why?
| | Analysis of Variance | 5 | 2009 | 1317 | 0.110 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 768 | 0.100 |
Why?
| | Dementia | 2 | 2008 | 261 | 0.100 |
Why?
| | Biomarkers | 4 | 2021 | 4092 | 0.100 |
Why?
| | Antibody Formation | 2 | 2022 | 298 | 0.100 |
Why?
| | Health Care Costs | 1 | 2017 | 418 | 0.100 |
Why?
| | Secretory Rate | 1 | 2013 | 16 | 0.100 |
Why?
| | Decision Support Systems, Clinical | 1 | 2017 | 253 | 0.100 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1164 | 0.100 |
Why?
| | Health Policy | 2 | 2024 | 397 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 209 | 0.100 |
Why?
| | Electronics | 1 | 2013 | 72 | 0.100 |
Why?
| | Arrhythmias, Cardiac | 1 | 2015 | 329 | 0.100 |
Why?
| | Interviews as Topic | 3 | 2010 | 803 | 0.100 |
Why?
| | Neurosurgical Procedures | 1 | 2014 | 204 | 0.090 |
Why?
| | Medical Records | 1 | 2013 | 180 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 365 | 0.090 |
Why?
| | Pandemics | 1 | 2021 | 1641 | 0.090 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 502 | 0.090 |
Why?
| | Age Factors | 8 | 2018 | 3256 | 0.090 |
Why?
| | Adenoma | 1 | 2014 | 219 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 496 | 0.090 |
Why?
| | Treatment Outcome | 8 | 2024 | 10923 | 0.090 |
Why?
| | Urban Health | 2 | 2009 | 95 | 0.090 |
Why?
| | Wakefulness | 1 | 2013 | 138 | 0.090 |
Why?
| | Memory | 3 | 2008 | 258 | 0.090 |
Why?
| | Follow-Up Studies | 5 | 2017 | 5112 | 0.090 |
Why?
| | Progestins | 1 | 2011 | 78 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 553 | 0.090 |
Why?
| | Equipment Design | 1 | 2013 | 519 | 0.090 |
Why?
| | Amenorrhea | 1 | 2011 | 31 | 0.090 |
Why?
| | Cognition | 3 | 2008 | 1179 | 0.090 |
Why?
| | Dopamine Agonists | 2 | 2008 | 43 | 0.090 |
Why?
| | Insulin | 1 | 2022 | 2448 | 0.090 |
Why?
| | Risk Assessment | 2 | 2017 | 3433 | 0.090 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2007 | 28 | 0.090 |
Why?
| | Birth Certificates | 1 | 2010 | 11 | 0.080 |
Why?
| | Estrone | 1 | 2010 | 36 | 0.080 |
Why?
| | Birth Rate | 2 | 2020 | 29 | 0.080 |
Why?
| | Cytokines | 2 | 2015 | 2080 | 0.080 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 44 | 0.080 |
Why?
| | Automobile Driving | 2 | 2010 | 150 | 0.080 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 14 | 0.080 |
Why?
| | Live Birth | 2 | 2020 | 65 | 0.080 |
Why?
| | Pregnancy Rate | 2 | 2020 | 67 | 0.080 |
Why?
| | Geographic Information Systems | 2 | 2010 | 46 | 0.080 |
Why?
| | Diet | 1 | 2018 | 1269 | 0.080 |
Why?
| | Fertilization in Vitro | 2 | 2020 | 84 | 0.080 |
Why?
| | Thyroxine | 2 | 2007 | 64 | 0.080 |
Why?
| | Cities | 1 | 2010 | 129 | 0.080 |
Why?
| | Abortion, Induced | 2 | 2008 | 101 | 0.080 |
Why?
| | Sex Factors | 5 | 2018 | 2044 | 0.080 |
Why?
| | United States | 6 | 2020 | 14938 | 0.080 |
Why?
| | Registries | 1 | 2017 | 2073 | 0.080 |
Why?
| | Personality | 1 | 2011 | 136 | 0.080 |
Why?
| | Electrical Equipment and Supplies | 1 | 2009 | 9 | 0.080 |
Why?
| | Stroke | 1 | 2017 | 1136 | 0.070 |
Why?
| | Rehabilitation Centers | 1 | 2009 | 38 | 0.070 |
Why?
| | Pattern Recognition, Automated | 1 | 2009 | 74 | 0.070 |
Why?
| | Telecommunications | 1 | 2009 | 21 | 0.070 |
Why?
| | Independent Living | 1 | 2010 | 107 | 0.070 |
Why?
| | Postmenopause | 1 | 2010 | 370 | 0.070 |
Why?
| | Progesterone | 3 | 2015 | 258 | 0.070 |
Why?
| | Rural Health | 1 | 2009 | 83 | 0.070 |
Why?
| | Mortality | 1 | 2011 | 355 | 0.070 |
Why?
| | Drug Interactions | 2 | 2007 | 404 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 8 | 0.070 |
Why?
| | Logistic Models | 2 | 2010 | 2065 | 0.070 |
Why?
| | Monitoring, Ambulatory | 1 | 2009 | 90 | 0.070 |
Why?
| | Foot | 1 | 2009 | 99 | 0.070 |
Why?
| | Exercise | 3 | 2010 | 2072 | 0.070 |
Why?
| | Ointments | 1 | 2007 | 24 | 0.070 |
Why?
| | Povidone-Iodine | 1 | 2007 | 11 | 0.070 |
Why?
| | Vaccinia | 1 | 2007 | 20 | 0.070 |
Why?
| | Life Change Events | 1 | 2009 | 153 | 0.070 |
Why?
| | Smallpox Vaccine | 1 | 2007 | 24 | 0.070 |
Why?
| | Vaccinia virus | 1 | 2007 | 43 | 0.070 |
Why?
| | Child, Preschool | 4 | 2018 | 11158 | 0.070 |
Why?
| | Pregnancy, Unplanned | 1 | 2008 | 46 | 0.070 |
Why?
| | CD4 Lymphocyte Count | 2 | 2020 | 280 | 0.070 |
Why?
| | Parkinsonian Disorders | 1 | 2007 | 43 | 0.070 |
Why?
| | Counseling | 1 | 2010 | 392 | 0.070 |
Why?
| | Disease Progression | 3 | 2015 | 2749 | 0.070 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 14 | 0.070 |
Why?
| | Atrophy | 1 | 2007 | 189 | 0.070 |
Why?
| | Population Surveillance | 1 | 2010 | 476 | 0.070 |
Why?
| | Antigens, Bacterial | 1 | 2007 | 125 | 0.060 |
Why?
| | Awareness | 1 | 2007 | 99 | 0.060 |
Why?
| | Antibodies, Bacterial | 1 | 2007 | 145 | 0.060 |
Why?
| | Time Perception | 1 | 2007 | 29 | 0.060 |
Why?
| | Antigens, Viral | 1 | 2007 | 179 | 0.060 |
Why?
| | Movement | 1 | 2009 | 281 | 0.060 |
Why?
| | Albumins | 1 | 2007 | 115 | 0.060 |
Why?
| | Tremor | 1 | 2007 | 97 | 0.060 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 237 | 0.060 |
Why?
| | Internship and Residency | 1 | 2016 | 1187 | 0.060 |
Why?
| | Suicide, Attempted | 1 | 2009 | 385 | 0.060 |
Why?
| | Blood-Brain Barrier | 1 | 2007 | 141 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 608 | 0.060 |
Why?
| | Infant | 3 | 2010 | 9574 | 0.060 |
Why?
| | Paroxetine | 1 | 2005 | 11 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 2116 | 0.060 |
Why?
| | Treatment Failure | 2 | 2022 | 351 | 0.060 |
Why?
| | Animals | 7 | 2023 | 37217 | 0.060 |
Why?
| | Attitude to Health | 1 | 2008 | 457 | 0.050 |
Why?
| | Administration, Oral | 1 | 2007 | 788 | 0.050 |
Why?
| | Neurologic Examination | 2 | 2008 | 128 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1941 | 0.050 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2024 | 78 | 0.050 |
Why?
| | Sexual Behavior | 1 | 2008 | 488 | 0.050 |
Why?
| | Health Promotion | 1 | 2010 | 750 | 0.050 |
Why?
| | Video Recording | 1 | 2025 | 181 | 0.050 |
Why?
| | Patient Compliance | 1 | 2008 | 598 | 0.050 |
Why?
| | Likelihood Functions | 2 | 2017 | 142 | 0.050 |
Why?
| | Child | 5 | 2018 | 21921 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 205 | 0.050 |
Why?
| | Follicle Stimulating Hormone, Human | 1 | 2023 | 12 | 0.050 |
Why?
| | Colorado | 2 | 2024 | 4555 | 0.050 |
Why?
| | Electronic Health Records | 2 | 2024 | 1092 | 0.050 |
Why?
| | Neurites | 1 | 2023 | 47 | 0.050 |
Why?
| | Family | 1 | 2008 | 677 | 0.050 |
Why?
| | Linear Models | 2 | 2020 | 852 | 0.050 |
Why?
| | Diffusion Tensor Imaging | 1 | 2023 | 76 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 710 | 0.050 |
Why?
| | Physical Fitness | 1 | 2004 | 206 | 0.050 |
Why?
| | Ritonavir | 1 | 2023 | 75 | 0.050 |
Why?
| | Temporomandibular Joint Dysfunction Syndrome | 1 | 2002 | 3 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2007 | 770 | 0.050 |
Why?
| | Emotions | 1 | 2007 | 568 | 0.050 |
Why?
| | Vaccines | 1 | 2007 | 402 | 0.050 |
Why?
| | Facial Pain | 1 | 2002 | 13 | 0.050 |
Why?
| | Physical Examination | 2 | 2018 | 238 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2007 | 855 | 0.050 |
Why?
| | Urban Population | 1 | 2025 | 482 | 0.050 |
Why?
| | Acids | 1 | 2002 | 19 | 0.050 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 128 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2023 | 154 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1323 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2025 | 290 | 0.050 |
Why?
| | Odds Ratio | 3 | 2010 | 1044 | 0.050 |
Why?
| | Ovarian Follicle | 1 | 2002 | 72 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3637 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 1818 | 0.040 |
Why?
| | Neuroimaging | 1 | 2023 | 263 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 165 | 0.040 |
Why?
| | Rheumatoid Factor | 1 | 2022 | 173 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 390 | 0.040 |
Why?
| | Puberty | 1 | 2002 | 152 | 0.040 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2022 | 114 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2020 | 12 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2007 | 858 | 0.040 |
Why?
| | Pregnancy, Multiple | 1 | 2020 | 17 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 287 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 214 | 0.040 |
Why?
| | Blastocyst | 1 | 2020 | 47 | 0.040 |
Why?
| | Leptin | 1 | 2002 | 242 | 0.040 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2212 | 0.040 |
Why?
| | Embryo Transfer | 1 | 2020 | 35 | 0.040 |
Why?
| | Fasting | 1 | 2002 | 283 | 0.040 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 5803 | 0.040 |
Why?
| | Prostaglandins | 1 | 2000 | 101 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 116 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2009 | 2049 | 0.040 |
Why?
| | Endotoxins | 1 | 2000 | 220 | 0.040 |
Why?
| | Oligodendroglia | 1 | 2001 | 177 | 0.040 |
Why?
| | Vaccination | 2 | 2024 | 1437 | 0.040 |
Why?
| | Decompression, Surgical | 1 | 1999 | 112 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1374 | 0.040 |
Why?
| | Depression | 1 | 2008 | 1466 | 0.040 |
Why?
| | Receptors, Nicotinic | 1 | 2001 | 344 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2018 | 88 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2030 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2022 | 898 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.030 |
Why?
| | Milk | 1 | 2018 | 123 | 0.030 |
Why?
| | Depressive Disorder, Major | 1 | 2001 | 374 | 0.030 |
Why?
| | Confidence Intervals | 2 | 2008 | 328 | 0.030 |
Why?
| | Depressive Disorder | 1 | 2000 | 391 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 451 | 0.030 |
Why?
| | Protons | 1 | 2017 | 92 | 0.030 |
Why?
| | Biostatistics | 1 | 2017 | 18 | 0.030 |
Why?
| | Incidence | 2 | 2017 | 2747 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2017 | 64 | 0.030 |
Why?
| | Psychological Tests | 1 | 2018 | 136 | 0.030 |
Why?
| | Electromyography | 1 | 1999 | 401 | 0.030 |
Why?
| | Thyrotropin | 2 | 2007 | 117 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 247 | 0.030 |
Why?
| | Stem Cells | 1 | 2001 | 599 | 0.030 |
Why?
| | Health Surveys | 2 | 2009 | 504 | 0.030 |
Why?
| | Drug Combinations | 2 | 2011 | 346 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2000 | 888 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1309 | 0.030 |
Why?
| | Viruses | 1 | 2018 | 161 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 849 | 0.030 |
Why?
| | Telemedicine | 1 | 2025 | 873 | 0.030 |
Why?
| | Neoplasms | 1 | 2011 | 2681 | 0.030 |
Why?
| | Fatty Liver | 1 | 2018 | 230 | 0.030 |
Why?
| | Escherichia coli | 1 | 2000 | 827 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2015 | 60 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2017 | 206 | 0.030 |
Why?
| | Systole | 1 | 2015 | 174 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1482 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 42 | 0.030 |
Why?
| | Electric Countershock | 1 | 2015 | 106 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1244 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 264 | 0.030 |
Why?
| | Risk | 1 | 2017 | 893 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 520 | 0.030 |
Why?
| | Phospholipids | 1 | 2015 | 219 | 0.030 |
Why?
| | Death, Sudden, Cardiac | 1 | 2015 | 188 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 117 | 0.030 |
Why?
| | Psychometrics | 1 | 2018 | 727 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2018 | 643 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 704 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3139 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2015 | 378 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1089 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4315 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 5798 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 896 | 0.020 |
Why?
| | Follicular Phase | 2 | 2004 | 39 | 0.020 |
Why?
| | Estrogens | 1 | 2015 | 365 | 0.020 |
Why?
| | Fatty Acids | 1 | 2015 | 444 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2018 | 674 | 0.020 |
Why?
| | Defibrillators, Implantable | 1 | 2015 | 306 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 764 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1482 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 611 | 0.020 |
Why?
| | Periodicity | 2 | 2001 | 57 | 0.020 |
Why?
| | Prognosis | 1 | 1999 | 3984 | 0.020 |
Why?
| | Abbreviated Injury Scale | 1 | 2010 | 22 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2010 | 109 | 0.020 |
Why?
| | Nasal Polyps | 1 | 2010 | 61 | 0.020 |
Why?
| | Life Expectancy | 1 | 2010 | 70 | 0.020 |
Why?
| | Amides | 1 | 2010 | 97 | 0.020 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 557 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6144 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 799 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2010 | 200 | 0.020 |
Why?
| | Income | 1 | 2010 | 201 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1098 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 174 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 709 | 0.020 |
Why?
| | Norgestrel | 1 | 1988 | 2 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 1988 | 17 | 0.020 |
Why?
| | Medroxyprogesterone | 1 | 1988 | 12 | 0.020 |
Why?
| | Benzodioxoles | 1 | 2010 | 116 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 448 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 177 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 192 | 0.020 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1988 | 35 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 41 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2008 | 15 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 286 | 0.020 |
Why?
| | Sheep | 2 | 2002 | 864 | 0.020 |
Why?
| | Parity | 1 | 1988 | 109 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2008 | 61 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2008 | 20 | 0.020 |
Why?
| | Smallpox | 1 | 2007 | 10 | 0.020 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 24 | 0.020 |
Why?
| | Employment | 1 | 2010 | 181 | 0.020 |
Why?
| | Diphtheria | 1 | 2007 | 21 | 0.020 |
Why?
| | Tetanus | 1 | 2007 | 26 | 0.020 |
Why?
| | Virus Shedding | 1 | 2007 | 46 | 0.020 |
Why?
| | Personal Satisfaction | 1 | 2010 | 214 | 0.020 |
Why?
| | Half-Life | 1 | 2007 | 146 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 85 | 0.020 |
Why?
| | Cause of Death | 1 | 2010 | 433 | 0.020 |
Why?
| | Commerce | 1 | 2008 | 80 | 0.020 |
Why?
| | Educational Status | 1 | 2010 | 462 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 166 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 555 | 0.020 |
Why?
| | Plasma Cells | 1 | 2007 | 73 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 165 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 48 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 501 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2007 | 42 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2007 | 91 | 0.020 |
Why?
| | Research | 1 | 2010 | 451 | 0.020 |
Why?
| | Photic Stimulation | 1 | 2007 | 252 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 60 | 0.020 |
Why?
| | Family Practice | 1 | 2011 | 463 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2007 | 92 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 2007 | 96 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2007 | 228 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2007 | 177 | 0.020 |
Why?
| | Age of Onset | 1 | 2008 | 514 | 0.020 |
Why?
| | Safety | 1 | 2008 | 347 | 0.020 |
Why?
| | Motor Skills | 1 | 2007 | 100 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2010 | 688 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2008 | 561 | 0.010 |
Why?
| | Mental Recall | 1 | 2007 | 207 | 0.010 |
Why?
| | Dopamine Agents | 1 | 2005 | 21 | 0.010 |
Why?
| | Virus Diseases | 1 | 2007 | 214 | 0.010 |
Why?
| | Down-Regulation | 1 | 2007 | 635 | 0.010 |
Why?
| | Vestibular Diseases | 1 | 2005 | 25 | 0.010 |
Why?
| | Dizziness | 1 | 2005 | 81 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1656 | 0.010 |
Why?
| | Gait Disorders, Neurologic | 1 | 2005 | 47 | 0.010 |
Why?
| | Self Efficacy | 1 | 2008 | 404 | 0.010 |
Why?
| | Inpatients | 1 | 2009 | 502 | 0.010 |
Why?
| | Memory, Short-Term | 1 | 2007 | 257 | 0.010 |
Why?
| | Presynaptic Terminals | 1 | 2005 | 91 | 0.010 |
Why?
| | Diet Records | 1 | 2004 | 83 | 0.010 |
Why?
| | Length of Stay | 1 | 2009 | 1238 | 0.010 |
Why?
| | Menarche | 1 | 2004 | 53 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1805 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1118 | 0.010 |
Why?
| | Overweight | 1 | 2008 | 571 | 0.010 |
Why?
| | Serotonin | 1 | 2005 | 322 | 0.010 |
Why?
| | Skin | 1 | 2007 | 754 | 0.010 |
Why?
| | Accidental Falls | 1 | 2005 | 192 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2011 | 1119 | 0.010 |
Why?
| | Heart Failure | 1 | 2015 | 2067 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 308 | 0.010 |
Why?
| | Follicular Fluid | 1 | 2002 | 5 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 2002 | 33 | 0.010 |
Why?
| | Neuraminidase | 1 | 2002 | 25 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 37 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1518 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2002 | 34 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2002 | 167 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 51 | 0.010 |
Why?
| | Caregivers | 1 | 2010 | 904 | 0.010 |
Why?
| | Thinness | 1 | 2002 | 95 | 0.010 |
Why?
| | Postprandial Period | 1 | 2002 | 110 | 0.010 |
Why?
| | Dihydro-beta-Erythroidine | 1 | 2001 | 6 | 0.010 |
Why?
| | Fura-2 | 1 | 2001 | 12 | 0.010 |
Why?
| | Nifedipine | 1 | 2001 | 28 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2002 | 150 | 0.010 |
Why?
| | Nicotinic Antagonists | 1 | 2001 | 36 | 0.010 |
Why?
| | Energy Intake | 1 | 2004 | 506 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2004 | 710 | 0.010 |
Why?
| | Luteal Phase | 1 | 2000 | 46 | 0.010 |
Why?
| | Area Under Curve | 1 | 2001 | 319 | 0.010 |
Why?
| | Prostaglandin Antagonists | 1 | 2000 | 3 | 0.010 |
Why?
| | Flurbiprofen | 1 | 2000 | 3 | 0.010 |
Why?
| | Depression, Chemical | 1 | 2000 | 20 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 2941 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 395 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 172 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 548 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2001 | 320 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2339 | 0.010 |
Why?
| | Fever | 1 | 2000 | 305 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1242 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1488 | 0.010 |
Why?
| | Sleep | 1 | 2002 | 799 | 0.010 |
Why?
| | Calcium | 1 | 2001 | 1180 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2001 | 4181 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5594 | 0.010 |
Why?
| | Neurons | 1 | 2001 | 1601 | 0.010 |
Why?
| | Mice | 1 | 2007 | 17814 | 0.010 |
Why?
|
|
Carlson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|